[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-alzheimer-type\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-alzheimer-type":264},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,60,95,128,160,194,227,252,275,300,324],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100633930","italian-validation-of-the-dna-scale-and-its-correlation-with-neurocognitive-variables-100633930",false,"NCT07533084","Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables","Italian Validation of the Dynamic Neurocognitive Adaptation (dNA) Scale and Its Correlation With Neurocognitive Variables","Inclusion Criteria (Stage #1):\n\n* Individuals aged ≥ 65 years residing in Italy;\n* Cognitively healthy individuals (HC);\n* Individuals with subjective memory complaints (SMC);\n* Individuals with mild cognitive impairment (MCI);\n* Individuals with probable Alzheimer's disease (AD).\n\nInclusion criteria (Stage #2 \\& Stage #3):\n\n* Individuals aged ≥ 65 years residing in Italy;\n* Cognitively healthy individuals (HC);\n* Individuals with subjective memory complaints (SMC);\n* Individuals with mild cognitive impairment (MCI);\n* Individuals with probable Alzheimer's disease (AD);\n* Individuals with Alzheimer's disease or other forms of dementia;\n* Individuals suffering from mental disorders clinically diagnosed.\n\nCognitively healthy individuals (HC):\n\n* MMSE score ≥24, or alternatively MoCA score ≥26;\n* No diagnosis of depression, MCI or any form of dementia;\n* Episodic memory performance within the normal range (Wechsler Memory Scale Logical Memory II ≥9 for 16 years of schooling or more; ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling; or alternatively for Prose Memory Test with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)\n\nIndividuals with Subjective Memory Complaints (SMC):\n\n* MMSE score ≥24, or alternatively MoCA score ≥26;\n* A significant memory impairment, reported by the subject, a family member, or the clinician;\n* No diagnosis of depression, MCI or any form of dementia;\n* Episodic memory performance within the normal range on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling (≥9 for 16+ years of schooling, ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling) or, alternatively, on the Prose Memory Test (with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)\n\nIndividuals with Mild Cognitive Impairment (MCI):\n\n* MMSE score between 19 and 23 inclusive (alternatively MoCA);\n* A decline in memory reported by the subject, a family member, or the clinician;\n* No diagnosis of depression or affected by any form of dementia, with preserved ability in activities of daily living;\n* Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.\n\nIndividuals with probable Alzheimer's disease (AD):\n\n* Insidious onset with atypical course: some criteria for probable AD are met, but the onset of symptoms may have been sudden, or there is a lack of objective evidence of progressive cognitive decline;\n* Mixed etiology presentation: All criteria for probable AD are met, with concomitant cerebrovascular disorders, or the presence of features typical of another dementia or the evidence of other neurological disorders or non-neurological comorbidities;\n* A decline in performance compared to the previous level of functioning is evident, as also described by a caregiver (often a family member)\n* Onset with memory disturbances, defined as difficulty learning new information or recalling it;\n* Onset with non-mnemonic symptoms (language symptoms, particularly difficulty finding the correct words; visuospatial symptoms: perceptual deficits characterized by failure to recognize objects, people, or written words; executive symptoms: difficulties with reasoning and critical thinking);\n* MMSE score \\\u003C 23 (alternatively MoCA \\\u003C 25);\n* Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.\n\nExclusion criteria (Stage #1):\n\n* Individuals aged \\\u003C 65 years;\n* Individuals not residing in Italy;\n* Individuals with depression or other psychiatric disorders;\n* Individuals with forms of dementia other than Alzheimer's disease.",true,"ALL","65 Years",{"count":20,"type":21},265,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this experimental multicentric intervention study is to validate, in Italian, the dynamic Neurocognitive Adaptation (dNA) Scale, which has already been validated in English, among a healthy elderly population (aged 65 and older) residing in Italy and patients with dementia or Alzheimer's Disease. dNA is a questionnaire designed to assess both current and past levels of engagement in physical, cognitive, creative, and social activities.\n\nThe study aims to recruit a total of 265 participants with mild cognitive impairment, subjective memory complaints, or dementia. These participants will be distributed among the 8 recruitment centers. Neuropsychological data, subjective measures, and MRI data will be collected and analyzed to address the following research questions: 1) Is there a positive correlation between scores on the dNA Scale and cognitive efficiency, as reflected in neuropsychological measures, such as episodic memory and executive functions? 2) Is there a correlation between dNA scores and improved functional connectivity within neural networks, such as the Default Network (DN)?\n\nParticipants recruited at the participating clinical centers will undergo:\n\n* A clinical interview, during which demographic and medical history information will be collected. The dNA Scale will be administered, along with a questionnaire assessing adherence to dietary habits typical of a Mediterranean diet (14-Item Mediterranean Diet Adherence Screener; MEDAS).\n* A neuropsychological assessment, aimed at evaluating general cognitive function with a particular focus on episodic memory and executive functions. The following tests will be administered: Mini-Mental State Examination (MMSE) or, alternatively, Montreal Cognitive Assessment (MoCA); Rey Auditory Verbal Learning Test (RAVLT); Trial Making Test (TMT) Form B; Digit Span Forward and Backward (WAIS or WAIS-III); and the Stroop Test.\n* Self-report questionnaires designed to assess depressive symptoms using the Geriatric Depression Scale (GDS) and anxiety symptoms using the Geriatric Anxiety Scale (GAS) (or alternatively the State-Trait Anxiety Inventory, STAI). Finally, the Cognitive Reserve Index Questionnaire will be administered to estimate Cognitive Reserve (CRIq).\n* Where available, MRI data previously acquired for clinical or diagnostic purposes will be included in the study and analyzed by the principal investigator.",[26,27,28,29,30,31,32],"Active Aging Individuals Aged 65 and Over","Aging","Mild Cognitive Impairment (MCI)","Dementia","Dementia Alzheimer Type","Subjective Memory Complaints","Probable Alzheimer's Disease",[34,35,36,37,38,39,40,41,42,43,44,45,46],"activities","habits","lifetime protective factors","adaptation","dynamic","neurocognitive","prevention","reserve","resilience","resistance","validation","well-being","aging","NOT_YET_RECRUITING","2026-06-09",{"date":50,"type":51},"2026-06-11","ACTUAL",{"date":53,"type":21},"2026-09",{"date":55,"type":21},"2027-11-27",{"name":57,"class":58},"Neuromed IRCCS","OTHER",8,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100571317","phase-1-rifaximin-ssd-in-dementia-trial-100571317","NCT06718686","Rifaximin SSD in Dementia Trial","Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia","RIDE","Inclusion Criteria:\n\n* Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate based on Clinical Dementia Rating Scale.\n* Males and Females Age ≥ 65 years\n* Community living with availability of caregiver to accompany participant to study visits and to participate in the study.\n* Able to consent or legal guardian who can consent (with participant assent).\n* Legally authorized representative (LAR) and caregiver for the study is the same individual.\n* Fluency (both participant and caregiver) in written and spoken English to participate in study visits.\n\nExclusion Criteria:\n\n* Dementia not due to AD or VaD\n* Clinically significant agitation or aggression (requiring treatment with antipsychotic medication)\n* Delusions and\u002For hallucinations\n* Severe psychopathology including major depression\n* Unstable, severe, or poorly controlled medical conditions evident from physical examination or clinical history\n* Visual and\u002For hearing disorder that prevents completion of neuropsychologic evaluations.\n* Diarrhea\n* Hypersensitivity to rifaximin, components of rifaximin,\n* and any rifamycin antimicrobial agent\n* Antibiotic use in the prior 6 months\n* Taking medications that interact with Rifaximin. P-glycoprotein (P-gp) inhibitor treatment is permitted as long as the use of P-gp inhibitors is discussed with the investigator.\n* History of alcohol and\u002For drug abuse\n* Participation in another investigational drug trial in the last 30 days",{"count":69,"type":21},20,"INTERVENTIONAL",[72,73],"PHASE1","PHASE2","Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.",[30,76],"Dementia Associated With Cerebrovascular Disease",[78,79,80,81,82],"dementia","rifaximin","gut-brain","Alzheimer's","vascular dementia","RECRUITING","2026-04-01",{"date":86,"type":51},"2026-04-03",{"date":88,"type":51},"2024-12-30",{"date":90,"type":21},"2027-12-30",{"name":92,"class":93},"Jasmohan Bajaj","FED",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":94},"100630262","global-collaborative-research-on-establishing-a-korean-cognitive-aging-cohort-100630262","NCT07485387","Global Collaborative Research on Establishing a Korean Cognitive Aging Cohort","Global Collaborative Research on Establishing a Korean Cognitive Aging Cohort That is Associated With the Einstein Aging Study","KoCoA cohort","Inclusion Criteria:\n\n* Adults aged 60 or older residing in the Republic of Korea\n* Samsung Galaxy smartphone users capable of using smartphone applications\n* Sufficient cognitive ability to understand and follow research instructions (MMSE score of 21 or above)\n* For individuals who do not meet the cognitive criteria, those who understand the study procedures and provide informed consent along with their legal guardian\n\nExclusion Criteria:\n\n* Diagnosis of dementia at baseline\n* Severe visual or hearing impairments that prevent participation in psychological assessments\n* Illiteracy that prevents participation in cognitive testing\n* Less than 80% compliance with the 2-day preliminary EMA protocol (one additional attempt allowed after re-training)\n* Current alcohol or substance abuse\n* Inability to ambulate or psychiatric conditions that prevent survey participation\n* Currently undergoing cancer treatment or received chemotherapy within the past 6 months","60 Years",{"count":105,"type":21},180,"The goal of this observational study is to learn how daily emotional stress affects cognitive function and inflammation in community-dwelling older adults aged 60 and older in Seoul, Republic of Korea. The main questions it aims to answer are:\n\nDoes daily psychological stress measured in real-time affect short-term and long-term cognitive function in older adults? Do pro-inflammatory cytokines (such as CRP, IL-6, IL-10, and TNF-α) mediate the relationship between emotional stress and cognitive decline? How do social support and social isolation influence cognitive function and inflammatory biomarkers over time?\n\nParticipants will:\n\nComplete baseline surveys assessing depression, cognitive function, and personal characteristics Use a smartphone app to answer brief surveys about their emotions, cognitive performance, and social interactions 1-6 times daily for two weeks Wear a Galaxy Watch to track sleep quality, heart rate, and physical activity Provide blood samples for inflammatory biomarker analysis Return for follow-up assessments at 6 months and 1 year\n\nThis study is part of an international collaboration to establish a Korean cohort comparable to the U.S. Einstein Aging Study, with the aim of developing culturally tailored dementia prevention strategies.",[28,30,108,109],"Chronic Pain","Depression - Major Depressive Disorder",[111,78,112,113,114,115,116,117,118],"mild cognitive impairment","chronic pain","depression","cognitive aging","longitudinal cohort","digital biomarkers","dementia biomarkers","behavioral phenotyping","2026-03-16",{"date":121,"type":51},"2026-03-20",{"date":123,"type":51},"2025-04-01",{"date":125,"type":21},"2037-12-31",{"name":127,"class":58},"Korea University",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":70,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":94},"100597879","validation-of-a-digital-intervention-to-rehabilitate-cognitive-resources-100597879","NCT07064226","Validation of a Digital Intervention to Rehabilitate Cognitive Resources","Transcultural and Multidimensional Validation of dIgital Rehabilitation Intervention of COgnitive Resources Domain-Oriented - Work Package 4","MI-RICORDO","Inclusion Criteria:\n\n1. Montreal Cognitive Assessment (MoCA) score \\> 17.79;\n2. Clinical Dementia Rating (CDR) Scale score ≤ 1;\n3. Education level \\> 3 years;\n4. Age ≥ 65 years;\n5. Informed consent to participate, confirmed by signing the consent form;\n6. Availability of a caregiver\u002Fstudy partner able to support the participant;\n7. Stable pharmacological treatment (past 3 months) with acetylcholinesterase inhibitors, if applicable.\n\nExclusion criteria:\n\n1. Presence of dysmetria or marked auditory\u002Fvisual or communication disorders preventing the participation to the trial;\n2. Presence of ongoing rehabilitation program at the time of enrollment or in the 3 months prior to enrollment;",{"count":137,"type":21},102,[139],"NA","The goal of this clinical trial is to learn if the use of a digital cognitive rehabilitation system named RICORDO, that is flexible and capable of adapting the rehabilitation pathway according to the needs and capacity of the patients will prove effective for subjects with Subjective Memory Complaint or with Mild Cognitive Impairment or with Mild Dementia.\n\nThe main questions it aims to answer are:\n\nWill the RICORDO rehabilitation treatment, lead to an improvement in the global cognitive level? Will the RICORDO rehabilitation treatment lead to improved activation of participants in managing their own health and healthcare? Researchers will compare the multidomain cognitive rehabilitation strategy of RICORDO digital solution, with a standard paper pencil rehabilitation care (usual care).\n\nParticipants will undergo a comprehensive neuropsychological evaluation immediately before, immediately after and six months after the completion of the rehabilitation program.\n\nBoth interventions, the experimental and the usual care, will last 5 weeks, with 3 weekly sessions of 45 minutes each and can be done autonomously by the patient at home.",[28,142,30],"Subjective Memory Complaint",[144,145,146,147,148,29,149,150],"telerehabilitation","Alzheimer disease","cognitive decline","cognitive rehabilitation","Digital medicine","Mild Cognitive Impairment","neuroimaging","2026-02-12",{"date":153,"type":51},"2026-02-13",{"date":155,"type":51},"2025-10-06",{"date":157,"type":21},"2027-09-30",{"name":159,"class":58},"Fondazione Don Carlo Gnocchi Onlus",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":70,"phases":171,"briefSummary":172,"conditions":173,"keywords":180,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":94},"100562036","phase-1-deep-repetitive-transcranial-magnetic-stimulation-rtms-of-the-precuneus-for-alzheimer-disease-ad-100562036","NCT06597942","Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)","Protocol for Maintaining and Improving Mental Status in Alzheimer's Disease (PROMIS-AD): a Pilot Study of Repetitive Transcranial Magnetic Stimulation of the Precuneus for Alzheimer&Amp;Amp;#39;s Disease","PROMIS-AD","Inclusion Criteria:\n\n* Age 60-100 at the start of the study\n* Established diagnosis of Alzheimer's Clinical Syndrome (which is also met through a diagnosis of Alzheimer's Dementia)\n* Agreement to participate in study and able to complete informed consent process\n* Have a caregiver\u002Fstudy partner who can accompany them to all study visits\n* Have a known alternate surrogate decision-maker (in case needed) who can accompany them to the informed consent visit (this person may be the study partner mentioned above)\n* Screening MMSE score of 18-26\n* Screening GDS score \\<6\n* Either 1) treated with memory-enhancing medication (cholinesterase inhibitor) for at least 2 months, 2) failed trial with no plan to re-trial, or 3) no trial planned during the course of the study for other reasons\n* No change in use of psychotropic medication for the treatment of depression, anxiety, ADHD, or psychosis for 2 weeks prior to the study\n\nExclusion Criteria:\n\n* Participant and\u002For their surrogate are unwilling or unable to provide informed consent\n* Currently pregnant or potentially pregnant\n* Diagnosis of a dementia or cognitive disorder due to a cause other than Alzheimer's Disease\n* Diagnosis of severe Dementia (CDR \\> 2.0) at the start of the study\n* History of substance use disorder currently not in sustained remission\n* Substance misuse within the past 6 months (excluding nicotine or caffeine)\n* History of stroke, traumatic brain injury with loss of consciousness, or other major neurologic disorder (e.g., epilepsy, Huntington's disease, Parkinson's disease)\n* History of seizure disorder or family history of seizure disorder in a first-degree relative\n* Poorly-controlled hypertension, cardiovascular disease, or cerebrovascular disease\n* History of any other major active medical, neurologic, or psychiatric illness affecting cognition (associated with cognitive impairment) or a participant's ability to safely and meaningfully participate in the study\n* Non-fluent in English (not native or functionally-native)\n* Contraindication to TMS or MRI including claustrophobia, MRI-incompatible or unknown metal in body (including facial tattoos with uknown or metallic inks), surgery within 60 days, certain implants (excluding dental fillings), or previous abnormal MRI results.\n* Has previous history of TMS treatment in the past (not TMS naïve)\n* Currently enrolled in a memory-enhancement study\n* Alteration in cognitive-enhancement medication dose within the past 2 months or active plans for dose alteration during the course of the study (previously unplanned changes that occur during the study will be examined on a case-by-case basis)\n* History of treatment with lecanemab, aducanumab, donanemab, or other monoclonal antibody treatment for Alzheimer's Disease (due to lack of knowledge surrounding the impacts of these treatments)\n* Currently or within the past 2 weeks taking any of the following classes of medication:\n\n  * Anticholinergic (e.g., tolterodine, benztropine)\n  * Sedating antihistamines (e.g., diphenhydramine)\n  * any drug that has significant anticholinergic or antihistaminic side effects (e.g., tricyclic antidepressant medications, mirtazapine).\n  * Benzodiazepines. While not a strict rule out, this will be decided on a case-by-case basis\n  * Antiepileptic agents. While not a strict rule out, this will be decided on a case-by-case basis\n  * Antipsychotic agents. While not a strict rule out, this will be decided on a case-by-case basis","100 Years",{"count":170,"type":21},54,[72,73],"The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work studying rTMS in Alzheimer's is mixed, but recent work studying rTMS of the precuneus is encouraging for both its short-term and long-term effects. The main questions this study aims to answer are:\n\n* Is deep rTMS of the precuneus feasible and tolerable in Alzheimer's?\n* Are there signs of positive brain changes in response to deep rTMS?\n* Is deep rTMS potentially efficacious for memory in Alzheimer's? Researchers will compare active stimulation to placebo stimulation while obtaining memory testing and measurements of the brain (imaging, scalp electrode measurements, bloodwork) to see if active treatment works to treat mild-to-moderate probable Alzheimer's Dementia.\n\nParticipants will:\n\n* Engage with memory testing, brain scans, and bloodwork during a comprehensive assessment\n* Visit the clinic 3 times for 12 consolidated rTMS sessions, followed by 4 once weekly maintenance sessions\n* Be offered a full open-label active treatment course after completing their treatment course if they are initially in the placebo group",[174,175,30,176,177,178,179],"Alzheimer&Amp;Amp;#39;s Disease","Alzheimer Disease","Mild Alzheimer&Amp;Amp;#39;s Disease","Moderate Alzheimer&Amp;Amp;#39;s Disease","Alzheimer&Amp;#39;s Disease (AD)","Alzheimer&Amp;#39;s Dementia",[181,182,183,184],"Clinical Trial","deep repetitive transcranial magnetic stimulation (deep rTMS)","precuneus","Mild-to-Moderate Probable Alzheimer's Dementia","2026-01-19",{"date":187,"type":51},"2026-01-21",{"date":189,"type":51},"2024-10-17",{"date":191,"type":21},"2026-10",{"name":193,"class":58},"University of California, Los Angeles",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":70,"phases":205,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":94},"100590257","cervical-lymphatico-venous-bypass-for-treatment-of-alzheimers-disease---proof-of-concept-study-clyveb-ad-1-study-100590257","NCT06965062","Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)","CLyVeB-AD-1","Inclusion Criteria:\n\n* Diagnosis of mild-moderate Alzheimer's disease (based on NIA-AA criteria);\n* Mini-Mental State Examination (MMSE) score 10-22;\n* Both participants and caregiver are able to understand English or Mandarin\n* Ability to provide informed consent or have a legally authorised representative to provide informed consent;\n* Good family support for post-treatment care and rehabilitation;\n* Fit for general anaesthesia\u002Fdeep sedation and surgery (ASA 1-2; excluding the diagnosis of Alzheimer's Disease).\n\nExclusion Criteria:\n\n* Cognitive decline due to prior infection or autoimmune diseases;\n* History of major cerebrovascular events or significant cardiovascular diseases;\n* Inability to have the head turned passively by at least 40 degrees;\n* Previous neck lymph node surgery or irradiation;\n* Active infection or malignancy;\n* Any contraindications to surgery or lumbar puncture\n* Any contraindication to MRI\u002FPET scan (eg. metallic implant that are not MRI-safe, known radiotracer allergy)\n* Experimental Alzheimer's Disease treatment within the past 6 months. • Current use of monoclonal antibodies treatment (eg. lecanemab\u002Fdonanemab)","50 Years","80 Years",{"count":204,"type":21},10,[139],"Alzheimer's disease (AD), one of the most common causes of dementia in Singapore and the developed world, is a neurodegenerative disorder with high socioeconomic impact. Accumulation of neurotoxic proteins (ie. amyloid, tau) are purported to lead to neuroinflammation, synaptic dysfunction and cognitive decline. The available pharmacotherapy provide limited symptomatic control, modest effect on disease progression with significant risk of side effects. Patients with AD eventually run out of effective pharmacotherapy and deteriorate.\n\nRecent evidence implicated the glymphatic system, meningeal lymphatics of the brain, and downstream drainage to the cervical lymphatic system in the accumulation of neurotoxic proteins in AD. This presented the opportunity for extra-cranial intervention, and has since been demonstrated in preclinical models. Based on these development, Xie and colleagues pioneered the deep cervical lymph node to venous bypass (DCLNV-BP) procedure with very promising early outcomes. The observed improvement had been attributed to enhanced clearance of the neurotoxic proteins. Knowledge gap and clinical equipoise remain, and clinical trials are required to understand the safety, mechanism of action, patient selection, and long-term outcomes.\n\nIn this proof of concept study, the investigators aim to assess safety and preliminary efficacy of DCLNV-BP in AD. An approach using objective clinical assessments, biomarkers and neuroimaging, to assess safety, evaluate preliminary efficacy and elucidate the possible mechanism underlying the observed effects, is undertaken. Since there are limited effective treatment for AD, this procedure is potentially ground breaking if it proves to halt progression or even improve patients' cognition, function and behaviour. Indirectly, this will have enormous health economic benefit for Singapore and the developed world that is facing the silver tsunami. Findings from this pilot study will lay the groundwork for future trials and research collaboration in AD and other neurodegenerative diseases.",[175,30,208,209,210],"Dementia Alzheimer's Type","Alzheimer's Disease","Alzheimer's Disease (AD)",[212,29,213,214,215,216,217,218],"Alzheimer's Disease","lymphatic surgery","lymphaticovenous anastomosis","lymphaticovenous bypass","cervical lymph node","meningeal lymphatic system","glymphatic system","2026-01-11",{"date":221,"type":51},"2026-01-13",{"date":123,"type":51},{"date":224,"type":21},"2030-03-31",{"name":226,"class":58},"Vincent Tay Khwee Soon",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":16,"sex":17,"minAge":201,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":70,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":94},"100616473","university-of-central-florida-music-study-100616473","NCT07306065","University of Central Florida Music Study","Scientific Proof of Music Therapy's Impact on Alzheimer's Disease","Inclusion Criteria:\n\n* 50 years old or older.\n\n  * 20 adults with no mild-cognitive impairment\n  * 20 adults with mild-cognitive impairment\n  * 20 adults with Alzheimer's disease\u002F dementia.\n* participant or the participant's legally authorized representative must be able to read or speak English and agree to comply with study procedures.\n* pregnant women may chose to participate\n\nExclusion Criteria:\n\n* 49 years and younger\n* prisoners\n* unable to understand English and provide consent",{"count":235,"type":21},60,[139],"The purpose of this study is to scientifically validate the impact of music therapy on Alzheimer's disease (AD) by analyzing molecular biomarkers in salivary exosomes. Exosomes are extracellular vesicles that carry molecular signals from brain cells, providing a non-invasive method to assess physiological changes.",[239,29,30],"Alzheimers Disease",[241,242,78],"Alzheimer s disease","music","2025-12-18",{"date":245,"type":51},"2025-12-29",{"date":247,"type":51},"2025-08-28",{"date":249,"type":21},"2026-03",{"name":251,"class":58},"University of Central Florida",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":259,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":94},"100604813","cardiac-amyloid-deposits-and-heart-dysfunction-in-alzheimers-disease-100604813","NCT07154394","Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease","Investigation of Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Alzheimer's Disease (Untersuchung Von Kardialen Amyloidablagerungen Als Ursache Einer Funktionseinschränkung Des Herzens Bei Alzheimer Demenz)","Inclusion Criteria:\n\n* Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease\n* No contraindications to undergo an MRI examination\n* No contraindications to undergo an Amyloid PET scan\n\nExclusion Criteria:\n\n* Patients with vascular dementia and confirmed other causes of dementia (e.g. stroke, vitamin deficiency, thyroid insufficiency, toxic causes such as alcohol)\n* Patients with pronounced cardiac preconditions\n* Pregnant and breastfeeding women","18 Years",{"count":261,"type":21},15,"This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.\n\nThe study will conduct additional PET\u002FMRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia.\n\nThis could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.",[264,149,265],"Dementia, Alzheimer Type","Cardiac Amyloidosis","2025-08-26",{"date":268,"type":51},"2025-09-04",{"date":270,"type":51},"2022-08-15",{"date":272,"type":21},"2025-09-14",{"name":274,"class":58},"University Hospital, Essen",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":281,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":70,"phases":284,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":297,"locationsCount":4},"100601804","phase-2-plans4care-personalized-dementia-care-on-demand-100601804","NCT07115251","Plans4Care: Personalized Dementia Care on Demand","Inclusion Criteria:\n\n1. A family, friend, or neighbor who self-identifies as having primary care responsibilities for a person with memory loss;\n2. \\>21 years of age;\n3. Able to use an internet capable device (computer, tablet or smart phone), and have stable internet access;\n\n6\\. Actively (e.g., past 6 months) managing a dementia-related care challenge.","21 Years",{"count":283,"type":21},160,[73],"The Plans4Care study is a research study funded by the National Institute on Aging (Grant# R44AG084365). The Plans4Care app is designed to help family caregivers address over 90 common care challenges such as behavioral symptoms (anxiety, agitation), functional changes and other concerns, and receive an action plan which provides easy-to-use non-drug strategies, resources, tips and education.\n\nThe goal of the study is to evaluate whether using the Plans4Care app will help you feel more confident providing care to your family member with dementia, better understand dementia, and enhance your own well-being. You also have the option to talk with a care advisor who can practice use of strategies or address concerns you may have.",[29,30,287,288],"Alzheimer Dementia (AD)","Memory Loss",[290],"Caregiver, Dementia, Memory Loss, Alzheimer","2025-08-04",{"date":293,"type":51},"2025-08-11",{"date":295,"type":21},"2025-08-30",{"date":157,"type":21},{"name":298,"class":299},"Plans4Care Inc","INDUSTRY",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":16,"sex":17,"minAge":259,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":94},"100563269","dynamic-light-scattering-ocular-measurement-in-the-detection-of-dementia-100563269","NCT06613971","Dynamic Light Scattering Ocular Measurement in the Detection of Dementia","DLS","1. All patients must be capable of an adequate ophthalmic evaluation and testing. This includes the ability to cooperate with the exam, sufficiently clear media (cornea, lens, vitreous) and sufficient pupillary dilation.\n2. Patients must be capable of providing informed consent.\n3. Patients who are not medically stable or who may be at significant risk to their health will not be eligible.\n4. Women of child bearing age must not be pregnant at the time of examination.",{"count":308,"type":21},50,"This is a human clinical study making a noninvasive measurement from a patient's eye to determine whether there is a quantitative difference in measurements between patients with and without the diagnosis of dementia.",[29,30],[29,312,313,314,305],"Spectroscopy","Dynamic Light Scattering Spectroscopy","Retinal Nerve Fiber Layer","2025-05-05",{"date":317,"type":51},"2025-05-08",{"date":319,"type":51},"2024-04-25",{"date":321,"type":21},"2028-04-25",{"name":323,"class":299},"MD Stem Cells",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":16,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":70,"phases":333,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":94},"100354127","reducing-african-americans-alzheimers-disease-risk-through-exercise-raate-100354127","NCT03890861","Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)\"","RAATE","Inclusion Criteria:\n\n1. self- identify as African American\n2. 60 years and older\n3. willing to accept randomization\n4. willing to attend group sessions\n5. lacking plans to move during the study period\n6. free of conditions that would make regular exercise unsafe (e.g. uncontrolled asthma, severe sickle cell disease, etc.)\n7. not engaged in regular physical activity\n8. Short Physical Performance Battery score \\>\u002F= 4\n9. physically capable of exercise,\n\nExclusion Criteria:\n\n1. cognitive impairment that would interfere with participating in group interactions\n2. unwilling to give written informed consent\n3. inability to attend group sessions\n4. conditions that prevent regular exercise\n5. conditions that the medical or principal investigator determine to warrant exclusion",{"count":332,"type":21},125,[139],"The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: 1) to determine if a physical activity intervention tailored to older African American adults is effective in modifying cognitive function associated with Alzheimer's Disease, 2) to determine if a physical activity intervention tailored to older African American adults is effective in modifying brain function and structure associated with Alzheimer's Disease, and 3) to determine if a physical activity promotion intervention tailored to African American adults is effective at enhancing physiological parameters. The primary endpoints for the study are episodic memory and executive functioning. The secondary outcomes include anthropometry, blood pressure, brain activation, cerebral blood flow, volume of whole brain and white matter hyperintensities, cardiorespiratory fitness, objectively measured physical activity, circulating hormones, and telomere length.",[264],[337,27,338,339,340],"African American","Physical activity","Cognition","Prevention","2024-11-20",{"date":343,"type":51},"2024-11-25",{"date":345,"type":51},"2019-08-09",{"date":347,"type":21},"2026-11",{"name":349,"class":58},"Pennington Biomedical Research Center"]